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Jean-Louis Vincent1*, John A Kellum2, Andrew Shaw3 and Michael G Mythen4Abstract
The choice of which intravenous solution to prescribe
remains a matter of considerable debate in intensive
care units around the world. Trends have been
moving away from using hydroxyethyl starch solutions
following concerns about safety. But are the available
data sufficient to clearly assess the risk-benefit balance
for all patients, and is there enough evidence of harm
to justify removing these drugs completely from our
hospitals?Sepsis [3] and 6S (Scandinavian Starch for Severe Sepsis/The choice of which intravenous solution to prescribe is
a question that arises many times a day in every inten-
sive care unit around the world. The pendulum has been
swinging away from hydroxyethyl starch (HES) solu-
tions, in part because of the revelations of fraudulent
studies conducted by Joachim Boldt [1]. Indeed, the per-
sistence of HES molecules in the body is of serious con-
cern and this issue can no longer be ignored by use of
‘newer’ starches. However, for any intravenous solution
(as for any drug), a balance between risks and benefit
must be considered. After all, diuretics, angiotensin-
converting enzyme inhibitors, and beta-blocking agents
can alter renal function in some patients but are also
highly effective agents in the management of the cardiac
patient.
Recent studies have provided a wealth of evidence
documenting the adverse effects of HES solutions, but
can they justify complete removal of these drugs from
the market? Such a decision would seem to require evi-
dence of harm in excess of benefit. Let’s try to assess this
balance (Figure 1) given the data provided by these re-
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The effects of HES solution on renal function in the Crys-
talloid versus Hydroxyethyl Starch Trial (CHEST) [2] were
somewhat discordant. The increase in creatinine with HES
was relatively minor and urine output was initially greater,
so there was actually less acute kidney injury when assessed
by the R and I stages of the Risk, Injury, Failure, Loss, and
End-stage renal disease criteria. There was a greater use of
renal replacement therapy, but the difference concerned
only 39 of 7,000 patients. The toxicity of HES solutions in
the Volume Substitution and Insulin Therapy in Severe
Septic Shock trial) [4] studies was more apparent, but much
larger doses (in some cases well in excess of recommenda-
tions or common practice) were used.Are the alternatives so safe?
Even if we accept the toxicity of HES solutions, the rela-
tive safety of other solutions is not entirely clear. Gelatin
solutions have not been well studied, but there do ap-
pear to be concerns for renal toxicity [5]. Similarly, there
is a renal failure risk associated with excessive adminis-
tration of other colloids [5]. With their high chloride
load, 0.9% saline solutions may also cause harm, includ-
ing an increased risk for dialysis [6,7]. Finally, hypotonic
solutions, such as lactated Ringer’s or Hartmann’s solu-
tion, may not be desired, and the effects of some constit-
uents, including acetate and gluconate, of other balanced
solutions have not been well studied. Although both the
CHEST [2] and 6S [4] trials provide evidence of com-
parative toxicity for saline versus HES in saline and
Ringer’s acetate versus HES in the same carrier, no avail-
able intravenous solution is free of potential adverse
effects.Do the available studies allow us to evaluate
benefit?
If we are to judge the risk-benefit ratio for each of the avail-
able fluids, we cannot look only at studies evaluating tox-
icity. HES, like other colloids, is believed to provide benefit
Figure 1 Benefits and risks of hydroxyethyl starch
(HES) solutions.
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in this context, is the time to reach resuscitation goals and
the volume of fluid required to achieve these goals. To
some extent, this was documented in the CHEST trial [2],
in which the administration of HES resulted in an initially
greater urine output, a less positive fluid balance, a higher
central venous pressure, and lower requirements for vaso-
pressor agents. Furthermore, the recent Colloids Compared
to Crystalloids in Fluid Resuscitation of Critically Ill Pa-
tients study, which included 3,000 patients, showed a less
positive fluid balance and lower 90-day mortality rates in
colloid than in crystalloid-treated patients, and the colloids
administered were primarily synthetic (Djillali Annane, per-
sonal communication). In contrast, the 6S study [4] could
not evaluate efficiency of resuscitation, because patients
had largely already achieved resuscitation goals prior to en-
rolment. In both studies, the central venous oxygen satur-
ation was 74% at baseline, and the initial lactate level was
only 2 mEq/L in the 6S study.
Thus, the recent trials, though excellent, provide only
half the information we need to be able to assess a risk-
benefit relationship. These studies have clearly charac-
terized the toxic effects of HES solutions but do not in-
form on potential benefit, except to demonstrate that
giving fluids to already-resuscitated patients does not
provide any! None of the intravenous fluids currently
available may be entirely safe, especially when given in
large amounts. All fluids should be considered as drugs,
and no drug is risk-free. Indeed, one can consider that
even oral fluids have their risks: beer, wine, and non-
alcoholic beverages, such as coffee and sugar-containing
beverages, should all be taken only in moderation, and
even water can be harmful if taken in excess.
Conclusions
We believe that decisions about intravenous fluid ther-
apy should be individualized on the basis of the availableevidence and the clinical context. Clinicians must defin-
itely be aware of the harmful effects attributable to HES,
and use of these solutions in patients with sepsis or in
bleeding patients should be undertaken only with ex-
treme caution and only when the benefits for the indi-
vidual patient are expected to exceed the risks for that
individual. Eliminating these solutions completely, on
the other hand, prevents their use even in situations in
which they are judged by physicians to have a positive
benefit-to-risk relationship. We believe that the US Food
and Drug Administration has made the right decision in
leaving the current HES solutions available but making
specific recommendations regarding restricted use of
these solutions in certain groups of patients and adding
a ‘black box’ warning about risks of excessive bleeding
[9]. This approach represents good regulatory medicine
because it does not impinge on provider autonomy but
ensures improved patient safety. We hope the European
Medicines Agency will take a similar view.
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